A panel within Japan’s Ministry of Health has recommended conditional approval for a stem cell treatment targeting Parkinson’s disease, developed by Sumitomo Pharma, according to reports from Bloomberg.
The therapy utilizes induced pluripotent stem cells (iPS), a groundbreaking technology that earned researcher Shinya Yamanaka the Nobel Prize. Sumitomo Pharma is expected to receive authorization for a period of seven years, during which further data collection will be required.
This decision marks a significant step in Japan’s strategy to foster a domestic regenerative medicine industry. The recommendation now moves to the Ministry of Health for final approval, a process typically considered a formality following expert endorsement.
Sumitomo Pharma anticipates its Parkinson’s disease therapy could generate over 100 billion yen (more than $640 million USD) in annual sales by the mid-2030s. The potential revenue highlights the growing market for advanced neurological treatments.
(RT)
Más noticias y más análisis de LaIguana.TV en YouTube, X, Instagram, TikTok, Facebook y Threads.
También para estar informado síguenos en:
Telegram de Miguel Ángel Pérez Pirela https://t.me/mperezpirela
Telegram de Laiguana.tv https://t.me/LaIguanaTVWeb
WhatsApp https://whatsapp.com/channel/0029VaHHo0JEKyZNdRC40H1I
El portal de Venezuela.
